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Cancer-testis antigen 7 (CT7, or melanoma-associated
antigen (MAGE)-C1) is the most frequently and consistently
expressed MAGE antigen in multiple myeloma (MM). CT7 is
an independent negative prognostic factor for MM, exhibits
a tissue-restricted expression pattern, and is highly
expressed during all stages of disease. Consequently, CT7 is
regarded as a potential target for immunotherapeutic strat-
egies in MM.
We sought to characterize CT7 protein expression in
the bone marrow (BM) of MM patients (pts) following allo-
geneic T cell-depleted (TCD)-HSCT, and to examine the
signiﬁcance of CT7-speciﬁc cellular and humoral immune
responses in these pts. We further aimed to determine CT7-
derived immunogenic epitopes and their associated allelic
restrictions.
Expression of CT7 in neoplastic CD138+ plasma cells was
evaluated by immunohistochemistry double staining in BM
biopsies from15 pts. CT7 expressionwas present in 13/15 pts.
Longitudinal analyses conducted in 10 of these pts showed
that low levels of CT7 protein were associated with better
outcomes. Conversely, the presence of CT7 protein in a high
percentage of myeloma cells was associated with a poorer
prognosis.
The nonamer FLAMLKNTV was predicted to have the
highest binding indices for HLA-A*0201 by reverse immu-
nology. Indeed, we conﬁrmed epitope-speciﬁc reactivity by
measuring intracellular IFN-g production to this peptide in
PBMC and BMMC from HLA-A*0201-expressing pts. The
tetramer HLA-A*0201-CT7-1087-1095 was generated to permit
longitudinal monitoring of CT7-speciﬁc T cell frequencies.
CT7-speciﬁc T cell frequencies were quantiﬁed by
tetramer staining in PBMC from 4 HLA-A*0201+ MM pts. Two
pts who developed marked tetramer+ T cell responses (up to
17.7 CD8+T cells/mL PB) entered CR. In contrast, 2 pts who
failed to develop prominent tetramer+ T cell responses
exhibited progressive disease. Phenotypic analyses revealed
the predominant presence of central memory CT7-speciﬁc T
cells in the BM,while effector memory cells dominated in the
PB. These initial clinical results suggest a potential relation-
ship between CT7-speciﬁc T cell frequencies and disease
course.
Humoral responses to a panel of tumor antigens,
including CT7, were examined longitudinally in 10 pts.
Analyses of CT7-speciﬁc antibody titers in one pt revealed
a response to a single CT7-derived peptide (CT71029-1048).
This response developed at a later time point than T cell
responses occurring in the same pt.
Finally, we report CT7-speciﬁc cytotoxic activity against
the CT7-expressing HLA-A*0201+ MM cell line U266 by T
cells expanded from a donor-reconstituted HLA-A*0201+MM
pt. Together, these results provide evidence of CT7-speciﬁc T
and B-cell responses that are able to target MM cells in
treatment responsive patients. Adoptive immunotherapeuticapproaches targeting CT7 may therefore prove useful in pts
with MM post allogeneic TCD-HSCT.86
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Background: Transformation of follicular lymphoma (FL) to
diffuse large B cell lymphoma (DLBCL) occurs in 30% of cases
at 10 years. Historically, survival with chemotherapy is poor.
Limited data are available on the role of autologous or allo-
geneic hematopoietic cell transplantation (autoHCT or
alloHCT) for DLBCL transformed from FL.
Methods: Descriptive analysis of 155 patients (age>18 years)
from 89 centers with transformation of FL to DLBCL reported
to the CIBMTR who had autoHCTor alloHCT from 1990-2009.
Pathology reports were reviewed in all cases to conﬁrm
transformation of FL to DLBCL. This is the largest epidemio-
logic series analyzing outcomes of HCT in transformed
DLBCL.
Results: Patients were classiﬁed into 3 groups consisting of
autoHCT (N¼108), alloHCT (N¼33), alloHCT (N¼14) after
prior autoHCT (performed for FL) with median ages of 56, 49,
51 years (yr) who received median of 3, 4, 5 lines of
chemotherapy prior to HCT, respectively. AutoHCT, alloHCT,
and alloHCTwith prior autoHCTgroups had 5 yr relapse rates
54% (95% conﬁdence intervals [CI] 45-64%), 33% (95% CI 17-
50%), 38% (95% CI 15-65%); 1 yr treatment related mortality
8% (95% CI 3-14%), 41% (95% CI 25-58%), 62% (95% CI 35-85%);
5 yr progression free survival (PFS) 36% (95% CI 27-46%), 18%
(95% CI 6-35%), 0%; 5 yr overall survival (OS) 50% (95% CI 40-
60%), 22% (95% CI 8-41%), 7% (95% CI 0-26%) respectively. The
size of the cohort did not allow multivariate analysis.
Univariate survival analysis of associations between risk
factors and post autoHCT and alloHCT outcomes showed age,
Karnofsky performance status, rituxan use, extranodal
disease and disease status at HCT (complete remission versus
primary induction failure) were not signiﬁcant factors. Use of
HLA identical sibling vs unrelated donors, ATG/campath vs
none, did not impact PFS/ OS after alloHCT. Chemotherapy vs
total body irradiation-based conditioning for autoHCT had
improved 3 yr PFS (46% [95% CI 35-57%] vs 24% [95% CI 9-
43%]; P ¼ .04); but 3 yr OS was not signiﬁcantly different.
Transformation >1 yr vs <1yr from diagnosis (dx) yielded
improvement in 1 yr PFS for the autoHCT (61% [95% CI 51-
71%] vs 29% [95% CI 11-53%]; P ¼ .01) and alloHCT groups
(44% [95% CI 24-64%] vs 11% [95% CI 0-38%]; P ¼ .03).
Transformation > 1 yr vs <1 yr from dx also had better 2 yr
OS in the alloHCT group (43% [95% CI 24-64%] vs 11% [95% CI
0-38%]; P ¼ .03). Time from dx to transformation was not
associated with OS after autoHCT. The Kaplan Meier graph
for PFS/ OS showed a plateau after 40 months only for
autoHCT group.
